Home>
Stocks>
Nectar Lifescience Ltd

Nectar Lifescience Ltd (NECLIFE)

₹33.75▲1.32%

Get free price alerts. Set up your Free investment account to get Live Prices. >

Overview

Fundamentals

Q3 '23 Results

Technicals

News and Events

Nectar Lifescience Ltd share Performance

₹33.6
₹34.8
₹33.75
0.44%
Low
Day's Volatility:3.56%
High
3.11%
₹16.5
₹45.7
₹33.75
51.11%
Low
52 Weeks Volatility:86.52%
High
35.41%

Returns %
1 Month Return	+ 3.17 %
3 Month Return	-22.1 %
1 Year Return	+ 98.84 %

Market Stats
Previous Close	₹₹34.20
Open	₹₹34.15
Volume	₹2.32L
Upper Circuit	₹-
Lower Circuit	₹-
Market Cap	₹₹766.97Cr

Company Information

Nectar Lifesciences Ltd (NLL or NECLIFE) is a globally acclaimed integrated pharmaceutical organization engaged in the manufacture and supply of high quality pharmaceutical products. With a vast network of production sites spread across three Indian states of Punjab, Himachal Pradesh, and Jammu, the organization provides top-notch active pharmaceutical ingredients (API), finished dosage forms, phytochemicals, and hard gelatin capsules to customers in over 90 countries across the world. In addition to manufacturing and marketing cephalosporins and phytochemicals, NECLIFE is also into contract manufacturing of APIs. Established in 1995, the organization has seen a number of expansions, the most recent being in 2019 when they established a unit in Portugal to take over marketing activities from the UK-based wing. They have also launched two new innovative products in the form of menthol capsules and pearl capsules. Focussing on providing quality products, NECLIFE has obtained approval from the Japanese MOH and is well-poised to continue its phenomenal rise in the global pharmaceuticals market.

Share Price: ₹33.75 per share as on 17 May, 2024 04:01 PM
Market Capitalisation: ₹766.97Cr as of today
Revenue: ₹452.16Cr as on December 2023 (Q4 23)
Net Profit: ₹1.57Cr as on December 2023 (Q4 23)
Listing date: 18 Jul, 2005
Chairperson Name: Sanjiv Goyal

Organisation	Nectar Lifescience Ltd
Headquarters	Chandigarh
Industry	Pharmaceuticals
E-voting on shares	Click here to vote

Key events for Nectar Lifescience Ltd

Nectar Lifescience Reports Strong Q3 Results - 26 Feb, 2024
Nectar Lifescience reports a 31.4% YoY increase in net sales, with quarterly net profit up by 116.87%. The company's EPS has also increased from Rs. 0.41 to Rs. 0.07. Nectar Life shares closed at 40.45 on February 23, 2024 (NSE) and have given returns of 64.43% over the last 6 months and 131.14% over the last 12 months.
Nectar Lifescience Ltd Drops 6.81% on BSE - 21 Feb, 2024
Nectar Lifescience Ltd's stock dropped by 6.81% to Rs 41.22, making it the fifth biggest loser in B group. On the BSE, 3.27 lakh shares were traded so far.
Nectar Lifesciences Shares Surge 27% Despite Lacklustre Revenue Growth - 19 Feb, 2024
Despite a surge of 27% in the last thirty days, Nectar Lifesciences' price-to-sales ratio of 0.6x may still make it look like a buy compared to the Pharmaceuticals industry in India. However, revenue growth has deserted the company recently, which is not something to boast about. The P/S might be low for a reason and requires further investigation to determine if it's justified.
Nectar Lifesciences Q3 FY24 Results Show 31.4% Increase in Topline - 17 Feb, 2024
Nectar Lifesciences reported a 31.4% increase in topline and a profit of ₹1.57cr for Q3 FY24, compared to a loss of ₹9.29cr in the same period last year. The EPS increased by 117.07% YoY. The company delivered -2.78% return in the last week, 50.92% return in the last 6 months, and 14.31% YTD return.

Fundamentals of Nectar Lifescience Ltd

Insights on Nectar Lifescience Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 1.02 Cr → 1.57 Cr (in ₹), with an average increase of 35.0% per quarter
POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 1.21% to 1.90% in Mar 2024 quarter
POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 394.6 Cr → 452.65 Cr (in ₹), with an average increase of 6.6% per quarter
POSITIVE IMPACT
Best in 1 Year
In the last 1 year, NECLIFE has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 123.6% return, outperforming this stock by 105.9%
NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 44.35% of holdings in Mar 2024 quarter
NEGATIVE IMPACT
Price Dip
In the last 3 months, NECLIFE stock has moved down by -22.1%
NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 22.31% to 21.63% in Mar 2024 quarter